Exercise of Warrants and Total Voting Rights

Exercise of Warrants and Total Voting Rights

20 January 2022

LONDON, U.K. AND PLANO, TX, U.S. . Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from a warrant holder to exercise warrants over 333,333 shares in the share capital of Belluscura ("the Warrant Shares") at an exercise price of 15 pence. The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £49,999.95.

The Warrant Shares were allotted on 20 January 2022. Application has been made for the Warrant Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to be on or around 26 January 2022. These shares will rank pari passu with the ordinary shares of the Company in issue.

Total voting rights

The Company's total issued capital, after the issue of the Warrant Shares, will be 114,168,777 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

Belluscura plc     www.belluscura.com

Robert Rauker, Chief Executive Officer                                                  via Walbrook PR

Anthony Dyer, Chief Financial Officer    

SPARK Advisory Partners Ltd (NOMAD)                                                Tel: +44 (0)20 3368 3550

Neil Baldwin      

Dowgate Capital Ltd (Broker)                                                                 Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers     

Walbrook PR Ltd (Media & Investor Relations)                                   Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Sam Allen                                                                      Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).